News and Events
A document related to the project entitled on Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention: Clinical and Economic Impact of Standard Versus Extended Duration is now available for feedback from all interested stakeholders.
Call for Feedback
Feedback Due By
Dual Antiplatelet Therapy Following Percutaneous Coronary...
Read this month’s issue of New at CADTH. Here, you’ll find the latest information on our products and services, corporate news, and news flashes of upcoming events across Canada.
Today CADTH is pleased to announce operational changes that will enhance our Common Drug Review and pan-Canadian Oncology Drug Review programs. These changes reflect our careful consideration of stakeholder feedback and input from the participating jurisdictions.
For complete details regarding the revised biosimilar review process and applicati...
View all News
The Institute Health Economics (IHE), the Canadian Agency for Drugs & Technologies in Health (CADTH) and Alberta Health are pleased to present “Doing the Right Thing... Right: Evidence Informing Clinical Decision-Making.”
Dr. Brian O’Rourke, President and Chief Executive Officer, CADTH, will be a keynote presenter at this forum, along with D...
The CADTH Lecture Series provides prominent scholars and opinion leaders with a forum to discuss pressing issues facing health technology assessment (HTA) and health care today.
Matthew Seftel, MD, MPH, FRCP, FRCPC
Head, Department of Medical Oncology and Hematology, CancerCare Manitoba
Associate Professor, Section of Hematology/Oncology, Depart...
April 15, 2018 - April 18, 2018
The CADTH Symposium is a must attend annual event for the Health Technology Assessment (HTA) community in Canada and beyond, and our 2018 event is no exception. It is an excellent opportunity to connect with Canadian and international experts to discuss what is being done — and what still needs to be done — to transform the way we manage health ...
View all Events